C12Y304/21104 - CPC Classification Index

ClassID:

116900 ⎘

C12Y304/21104 - CPC Classification

Classification description:

Hydrolases acting on peptide bonds, i.e. peptidases (3.4); Serine endopeptidases (3.4.21) Mannan-binding lectin-associated serine protease-2 (3.4.21.104)

Recent Application in this class:

20260098080

2026-04-09

A MODIFIED PROTEIN SCAFFOLD AND USE THEREOF

20250154284

2025-05-15

MASP-2-TARGETTING ANTIBODIES AND USES THEREOF

20240352463

2024-10-24

CONJUGATE

20240343830

2024-10-17

Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation

20240342278

2024-10-17

ANTIBODIES SPECIFICALLY BINDING TO MASP-3 FOR THE TREATMENT OF VARIOUS DISEASES AND DISORDERS

20240293465

2024-09-05

Methods for Treating and/or Preventing Graft-Versus-Host Disease and/or Diffuse Alveolar Hemorrhage and/or Veno-Occlusive Disease Associated with Hematopoietic Stem Cell Transplant

20240092938

2024-03-21

COMPOSITIONS FOR INHIBITING MASP-2 DEPENDENT COMPLEMENT ACTIVATION

20230391889

2023-12-07

Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation

20230125933

2023-04-27

MANNAN BINDING LECTIN SERINE PEPTIDASE 2 (MASP2) IRNA COMPOSITIONS AND METHODS OF USE THEREOF

#10

20210290684

2021-09-23

Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant

#11

20210275667

2021-09-09

Antibodies specifically binding to MASP-3 for the treatment of various diseases and disorders

#12

20210054099

2021-02-25

Compositions for inhibiting MASP-2 dependent complement activation

#13

20210047433

2021-02-18

Methods for treating conditions associated with MASP-2 dependent complement activation

#14

20200317510

2020-10-08

Antibodies specifically binding to MASP-3 for the treatment of various diseases and disorders

#15

20200190215

2020-06-18

Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation

#16

20190125802

2019-05-02

Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant

#17

20190119402

2019-04-25

Compositions for inhibiting MASP-2 dependent complement activation

#18

20180291112

2018-10-11

Methods for Treating Disseminated Intravascular Coagulation by Inhibiting MASP-2 Dependent Complement Activation

#19

20180140697

2018-05-24

Antibodies specifically binding to MASP-3 for the treatment of various diseases and disorders

#20

20170233494

2017-08-17

Methods for Treating Disseminated Intravascular Coagulation by Inhibiting MASP-2 Dependent Complement Activation

#21

20170233493

2017-08-17

Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation

#22

20170137537

2017-05-18

Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation

#23

20170088632

2017-03-30

Compositions for inhibiting MASP-2 dependent complement activation

#24

20160002349

2016-01-07

Compositions for inhibiting MASP-2 dependent complement activation

#25

20120282263

2012-11-08

Compositions for inhibiting MASP-2 dependent complement activation

#26

20110091450

2011-04-21

Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation

#27

20110020337

2011-01-27

METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION

#28

20100074899

2010-03-25

METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION

#29

20070172483

2007-07-26

Methods for treating conditions associated with MASP-2 dependent complement activation

#30

20060018896

2006-01-26

Methods for treating conditions associated with lectin-dependent complement activation